All questions are shown as received by the Trust.
Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Lonsurf (Trifluridine – tipiracil)
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
Q2. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. Atezolizumab (Tecentriq)
b. Durvalumab (Imfinzi)
c. Nivolumab (Opdivo)
d. Pembrolizumab (Keytruda)
e. Chemotherapy
f. Radiotherapy
g. Chemotherapy AND Radiotherapy
Q3. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:
a. Avelumab + Axitinib (Bavencio + Inlyta)
b. Cabozantinib (Cometriq)
c. Nivolumab (Opdivo)
d. Nivolumab + Cabozantinib (Opdivo + Cometriq)
e. Nivolumab + Ipilimumab (Opdivo + Yervoy)
f. Pembrolizumab + Lenvatinib (Keytruda + Kisplyx)
